The "Lichen Planus - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
A detailed picture of the Lichen Planus pipeline landscape is provided which includes the disease overview and Lichen Planus treatment guidelines.
The assessment part of the report embraces, in depth Lichen Planus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lichen Planus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Lichen Planus Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Lichen Planus targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Lichen Planus pipeline report covers 8+ companies. Some of the key players include AFYX Therapeutics (Clobetasol Propionate), Celgene (Apremilast), Intas Pharmaceuticals (Nanosomal tacrolimus), etc.
Scope of the report
- The Lichen Planus report provides an overview of therapeutic pipeline activity for Lichen Planus across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Lichen Planus therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
- Detailed Lichen Planus Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Lichen Planus
Key Topics Covered:
1. Report Introduction
2. Lichen Planus
2.1. Lichen Planus Disease Overview
2.2. Lichen Planus History
2.3. Lichen Planus Symptoms
2.4. Lichen Planus Causes
2.5. Lichen Planus Pathophysiology
2.6. Lichen Planus Diagnosis
2.6.1. Diagnostic Guidelines
3. Lichen Planus Current Treatment Patterns
3.1. Treatment Guidelines
4. Lichen Planus - An Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Lichen Planus companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Lichen Planus Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis
4.1.2.2. Lichen Planus Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono/Combination)
4.2.3. Assessment by Route of Administration
4.2.4. Assessment by Molecule Type
4.2.5. Assessment by MOA
5. Lichen Planus Pipeline Therapeutics
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.3. Early Stage Products (Phase-I)
5.4. Pre-clinical and Discovery Stage Products
5.5. Inactive Products
6. Lichen Planus Products Analysis
6.1. Product Profiles
6.1.1. Clobetasol Propionate- AFYX Therapeutics
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. Apremilast- Celgene
6.1.3. Nanosomal tacrolimus- Intas Pharmaceuticals
7. Recent Technologies
8. Lichen Planus Key Companies
8.1. AFYX Therapeutics
8.2. Incyte Corporation
8.3. Takeda
8.4. Kiniksa Pharmaceuticals
8.5. Celgene
8.6. Intas Pharmaceuticals
8.7. Onxeo
8.8. Intas Pharmaceuticals
9. Lichen Planus Key Products
9.1. Clobetasol propionate oral
9.2. Ruxolitinib
9.3. Amlexanox
9.4. KPL 716
9.5. Apremilast
9.6. Tacrolimus
9.7. Research programme: lichen planus therapeutics
9.8. Nanosomal tacrolimus
10. Dormant and Discontinued Products
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. Lichen Planus - Unmet Needs
12. Lichen Planus - Future Perspectives
13. Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/sdi4tq
View source version on businesswire.com: https://www.businesswire.com/news/home/20191021005437/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
